Loading stock data…
Lantern Pharma Inc (LTRN)
$4.07+0.21 (+5.44%)
After Hours$4.02-0.05 (-1.23%)· Last close Jun 29
Lantern Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantern Pharma Inc. in the Healthcare sector is trading at $4.07 with a market capitalization of $48M. Wall Street consensus targets $20.00 (2 analysts), implying a +391.4% move over the next 12 months. The stock is currently 29% below its 52-week high of $5.74, remaining 26.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +391.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.41M↑ | -$4.20M↑ | -$4.35M↑ | -$4.65M↑ | -$4.77M |
| Net Income | -$3.33M↑ | -$4.07M↑ | -$4.18M↑ | -$4.33M↑ | -$4.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$47.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-461.79%
Volume
Today's trading volume
262,512
Recent News
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
Need a quote from a Motley Fool analyst? Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements can be found in our annual report on Form 10-K for the year ended December 31, 2024, which is on file with the SEC and available on our website.
Promising Penny Stocks To Consider In May 2026
The United States market has shown impressive growth, with a 1.1% increase over the last week and a substantial 27% rise over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. Penny stocks, while an older term, continue to capture attention as they often represent smaller or newer companies that provide growth opportunities at lower price points. By focusing on those with strong financial health and solid fundamentals, investors can uncover...
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Quantum Cyber (NASDAQ:QUCY) shares rose 163.0% to $0.85 during Wednesday's regular session. The market value of their outstanding shares is at $4.0 million. Whitehawk Therapeutics (NASDAQ:WHWK) stock moved upwards by 29.59% to $5.08. The company's market cap stands at $193.8 million. As per the news, the Q1 earnings report came out 4 days ago. Replimune Group (NASDAQ:REPL) stock moved upwards by 29.09% to $5.28. The market value of their outstanding shares is at $320.8 million. MaxCyte (
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Lantern Pharma Inc (LTRN) showcases clinical progress and AI-driven innovations while addressing funding needs and operational hurdles.
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating soft tissue sarcomas. According to Lantern Pharma, the ODD designation applies in the United States […]